Danaher Corporation has announced the acquisition of Abcam, a UK-based life sciences supplier, for $5.7 billion. Abcam, a producer of research items such as antibodies and biomarkers, engaged in discussions with 20 other potential buyers before they decided to complete the acquisition with Danaher. This acquisition follows a strategic review by Abcam to improve shareholder value, possibly through a company sale. While retaining its standalone status, Abcam will operate within Danaher’s life sciences section to contribute to its objective of mapping complex diseases and enhancing drug discovery. The companies expect to close the deal in mid-2024, and we will finance it with cash and the issuance of commercial paper.
To read more, click here.
[Source: MM+M, August 28th, 2023]